Belvedere Trading’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Belvedere Trading’s Portfolio LABU Stock Details LABU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,200	Closed	-$85.3K	–	889
2025 Q4	$85.3K	Buy	1,200 +500	+71%	+$68.7K	﹤0.01%	589
2025 Q3	$3.28K	Sell	700 -200	-22%	-$14.1K	﹤0.01%	841
2025 Q2	$2.56K	Sell	900 -1,500	-63%	-$79.6K	﹤0.01%	761
2025 Q1	$94.2K	Buy	2,400 +1,500	+167%	+$128K	﹤0.01%	436
2024 Q4	$4.05K	Buy	900 +100	+13%	+$11.8K	﹤0.01%	759
2024 Q3	$5.15K	Buy	800 +400	+100%	+$52.2K	﹤0.01%	664
2024 Q2	$2.27K	Sell	400 -1,000	-71%	-$107K	﹤0.01%	639
2024 Q1	$186K	Buy	+1,400	New	+$183K	﹤0.01%	353

Other funds holding LABU

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

MIG

McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Belvedere Trading's LABU Position: Q1 2026 in Review

Belvedere Trading increased its Direxion Daily S&P Biotech Bull 3X ETF (LABU) stake by 2,609% in Q1 2026, buying an estimated $1.03M and bringing the position to 6,501 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #144.

Belvedere Trading first reported a position in LABU in Q3 2022 and has held it in 8 quarters since. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2026.

Belvedere Trading held 6,501 shares of Direxion Daily S&P Biotech Bull 3X ETF worth $1.08M as of Q1 2026.
Belvedere Trading bought 6,261 Direxion Daily S&P Biotech Bull 3X ETF shares in Q1 2026, an estimated $1.03M.
Direxion Daily S&P Biotech Bull 3X ETF made up ﹤0.01% of Belvedere Trading's portfolio in Q1 2026, its #144 holding.
Belvedere Trading first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q3 2022 and has held it in 8 quarters since.
33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2026.

Based on Belvedere Trading's 13F filing for Q1 2026, filed 12 May 2026.